ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
66 hedge funds and large institutions have $22.9M invested in Adaptimmune Therapeutics in 2025 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
16% less funds holding
Funds holding: 79 → 66 (-13)
58% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 19
66% less capital invested
Capital invested by funds: $67M → $22.9M (-$44.2M)
Holders
66
Holding in Top 10
1
Calls
$22K
Puts
$3K
Top Buyers
| 1 | +$1.12M | |
| 2 | +$643K | |
| 3 | +$326K | |
| 4 |
Morgan Stanley
New York
|
+$274K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$172K |
Top Sellers
| 1 | -$6.37M | |
| 2 | -$2.62M | |
| 3 | -$385K | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$338K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$286K |